5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is segmented By Cancer Type (Renal Cancer Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Other Cancer Types), By Therapeutic Class, By Pharmacologic Class, By Diagnostics and Geography.
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 4.1% during the forecast period. The major factors driving the growth of the market in the Asia region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, the major countries contributing to kidney cancer cases in Asia are China and Japan. These countries were among the highest cases of kidney cancer worldwide. Furthermore, according to the International Agency for Research on Cancer, in 2018, there were about 148,947 new kidney cancer cases and the mortality was approximately 79,149 cases in Asia.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Asia-Pacific kidney cancer therapeutics & diagnostics market is segmented by cancer type, therapeutic class, pharmacologic class, diagnostics, and geography.
|By Cancer Type|
|Renal Cancer Carcinoma|
|Clear Cell Renal Cell Carcinoma|
|Papillary Renal Cell Carcinoma|
|Chromophobe Renal Cell Carcinoma|
|Other Cancer Types|
|By Therapeutic Class|
|By Pharmacologic Class|
|Cytokine Immunotherapy (IL-2)|
Report scope can be customized per your requirements. Click here.
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule in the kidney that transport primary urine. It is the most common type of kidney cancer. Renal cell carcinoma mainly affects the population who are older, usually between ages 50 and 70.
The factors that are driving the market that includes growing awareness among people about cancer, rising geriatric population, and rising incidence of renal cancer. As per Cancer Australia, in 2019, it was estimated that the age-standardized mortality rate due to kidney cancer was 3.3 deaths per 100,000 persons (4.7 for males and 2.1 for females) in Australia. The mortality rate for kidney cancer is expected to increase with age which shows a positive impact on the market. Thus, increasing cases of kidney cancer, the growing geriatric population along with that awareness about cancer are the major factors driving the segment and expected to do over the forecast period.
To understand key trends, Download Sample Report
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Bayer AG, F. Hoffmann-La Roche Ltd, Eisai.Co.Ltd, Novartis AG, Pfizer Inc, Abbott Laboratories, Amgen Inc, and Seattle Genetics.
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.3.2 Preference for Generic Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Renal Cancer Carcinoma
5.1.2 Clear Cell Renal Cell Carcinoma
5.1.3 Papillary Renal Cell Carcinoma
5.1.4 Chromophobe Renal Cell Carcinoma
5.1.5 Other Cancer Types
5.2 By Therapeutic Class
5.2.1 Targeted Therapy
5.3 By Pharmacologic Class
5.3.1 Angiogenesis Inhibitors
5.3.2 Monoclonal Antibodies
5.3.3 mTOR Inhibitors
5.3.4 Cytokine Immunotherapy (IL-2)
5.4 By Diagnostics
5.4.2 Intravenous Pyelogram
5.4.3 CT Scan
5.4.6 Other Diagnostics
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 F. Hoffmann-La Roche Ltd
6.1.4 Novartis AG
6.1.5 Pfizer Inc
6.1.6 Abbott Laboratories
6.1.7 Amgen Inc
6.1.8 Seattle Genetics
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments